Cost-Effectiveness Analysis of Sequential Treatment Strategies for Moderate to Severe Crohn’s Disease in Spain: Where Should Biosimilar Ustekinumab Be Positioned?
Positioning bsUST as a first line of treatment appears to be cost effective and an efficient alternative from the NHS perspective in Spain. Additionally, none of the alternative sequences proved to be cost effective compared with the sequence starting with bsADA-bsUST. bsUST may significantly impact Crohn's disease management in Spain, improving patient access due to its lower drug acquisition costs.
Authors
- Mónica Cerezales (ORCID: https://orcid.org/0000-0001-6705-006X)
- Marcelo Alejandro Guigini
- José Ignacio Peinado-Fabregat
- B Acosta
- Carlos Crespo
- Francisco Ibáñez
- Iago Rodríguez-Lago
Institutions
- Universidad de Deusto (ES)
- Universidad de Oviedo (ES)
- BioCruces Health research Institute (ES)
- Ta Solutions (China) (CN)
- Complejo Hospitalario Universitario de Santiago (ES)
- Hospital de Galdakao (ES)
- Instituto de Investigación Sanitaria de Santiago (ES)
- Barcelona Activa (ES)
- Barcelona School of Economics (ES)
- Universitat de Barcelona (ES)
- Fresenius Kabi (Czechia) (CZ)
Publication Details
- Journal
- PharmacoEconomics - Open
- Published
- 2026-03-09
- DOI
- https://doi.org/10.1007/s41669-026-00642-1
- Primary Topic
- Biosimilars and Bioanalytical Methods
- Type
- article
- Field-Weighted Citation Impact
- 0.00
Funders
- Eusko Jaurlaritza